Treatment features of systemic chemotherapy in young adults with unresectable advanced or recurrent gastric cancer

References

• World Health OrganizationInternational Agency for Research on CancerGLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012 v1.02012 Available from: http://globocan.iarc.fr/Pages/fact_sheets_population.aspxAccessed August 1, 2016
   Google Scholar
• KataiHSasakoMSanoTMaruyamaKGastric carcinoma in young adultsJpn J Clin Oncol19962631391438656553
   PubMed Web of Science ®Google Scholar
• Al-RefaieWBHuCYPistersPWChangGJGastric adenocarcinoma in young patients: a population-based appraisalAnn Surg Oncol201118102800280721424881
   PubMed Web of Science ®Google Scholar
• TakatsuYHikiNNunobeSClinicopathological features of gastric cancer in young patientsGastric Cancer201619247247825752270
   PubMed Web of Science ®Google Scholar
• LiuSFengFXuGClinicopathological features and prognosis of gastric cancer in young patientsBMC Cancer20161647827418046
   PubMed Web of Science ®Google Scholar
• QiuMZWangZQZhangDSClinicopathological characteristics and prognostic analysis of gastric cancer in the young adult in ChinaTumour Biol201132350951421181464
   PubMedGoogle Scholar
• DhobiMAWaniKAParrayFQGastric cancer in young patientsInt J Surg Oncol2013201398165424381753
   PubMedGoogle Scholar
• SantoroRCarboniFLepianePEttorreGMSantoroEClinicopathological features and prognosis of gastric cancer in young European adultsBr J Surg200794673774217330827
   PubMed Web of Science ®Google Scholar
• ParkJCLeeYCKimJHClinicopathological aspects and prognostic value with respect to age: an analysis of 3,362 consecutive gastric cancer patientsJ Surg Oncol200999739540119347884
   PubMed Web of Science ®Google Scholar
• HsiehFJWangYCHsuJTLiuKHYehCNClinicopathological features and prognostic factors of gastric cancer patients aged 40 years or youngerJ Surg Oncol2012105330430922116742
   PubMed Web of Science ®Google Scholar
• KoeaJBKarpehMSBrennanMFGastric cancer in young patients: demographic, clinicopathological, and prognostic factors in 92 patientsAnn Surg Oncol20007534635110864341
   PubMed Web of Science ®Google Scholar
• MaeharaYEmiYTomisakiSAge-related characteristics of gastric carcinoma in young and elderly patientsCancer1996779177417808646673
   PubMed Web of Science ®Google Scholar
• KimDYJooJKRyuSYParkYKKimYJKimSKClinicopathologic characteristics of gastric carcinoma in elderly patients: a comparison with young patientsWorld J Gastroenterol2005111222615609390
   PubMed Web of Science ®Google Scholar
• ChoiJHChungHCYooNCGastric cancer in young patients who underwent curative resection. Comparative study with older patientsAm J Clin Oncol199619145488554035
   PubMed Web of Science ®Google Scholar
• NakamuraRSaikawaYTakahashiTRetrospective analysis of prognostic outcome of gastric cancer in young patientsInt J Clin Oncol201116432833421301918
   PubMed Web of Science ®Google Scholar
• IsobeTHashimotoKKizakiJCharacteristics and prognosis of gastric cancer in young patientsOncol Rep2013301434923674196
   PubMed Web of Science ®Google Scholar
• KoizumiWNaraharaHHaraTS-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trialLancet Oncol20089321522118282805
   PubMed Web of Science ®Google Scholar
• YamadaYHiguchiKNishikawaKPhase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancerAnn Oncol201526114114825316259
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research NetworkComprehensive molecular characterization of gastric adenocarcinomaNature2014513751720220925079317
   PubMed Web of Science ®Google Scholar
• ChoSYParkJWLiuYSporadic early-onset diffuse gastric cancers have high frequency of somatic CDH1 alterations, but low frequency of somatic RHOA mutations compared with late-onset cancersGastroenterology2017153253654928522256
   PubMed Web of Science ®Google Scholar
• BangYJvan CutsemEFeyereislovaATrastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialLancet2010376974268769720728210
   PubMed Web of Science ®Google Scholar
• EisenhauerEATherassePBogaertsJNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Eur J Cancer200945222824719097774
   PubMed Web of Science ®Google Scholar
• KandaYInvestigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplant201348345245823208313
   PubMed Web of Science ®Google Scholar
• YuJHeYGuoZAge trend of the male to female sex ratio in surgical gastric cancer patients at a single institutionWorld J Surg Oncol20141226927225141903
   PubMed Web of Science ®Google Scholar
• BandoHYamadaYTanabeSEfficacy and safety of S-1 and oxaliplatin combination therapy in elderly patients with advanced gastric cancerGastric Cancer201619391992626474989
   PubMed Web of Science ®Google Scholar
• CorsoGCarvalhoJMarrelliDSomatic mutations and deletions of the E-cadherin gene predict poor survival of patients with gastric cancerJ Clin Oncol201331786887523341533
   PubMed Web of Science ®Google Scholar
• ZhuLLiZWangYMicrosatellite instability and survival in gastric cancer: a systematic review and meta-analysisMol Clin Oncol20153369970526137290
   PubMed Web of Science ®Google Scholar
• HironakaSUedaSYasuiHRandomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trialJ Clin Oncol201331354438444424190112
   PubMed Web of Science ®Google Scholar
• WilkeHMuroKvan CutsemERamucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trialLancet Oncol201415111224123525240821
   PubMed Web of Science ®Google Scholar
• ShitaraKTakashimaAFujitaniKNab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trialLancet Gastroenterol Hepatol20172427728728404157
   PubMed Web of Science ®Google Scholar
• BandoHShimodairaHFujitaniKA phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancerEur J Cancer201891869129353164
   PubMed Web of Science ®Google Scholar
• TakashimaAShitaraKFujitaniKPeritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trialGastric Cancer2018
   Web of Science ®Google Scholar
• YamamotoMRashidOMWongJSurgical management of gastric cancer: the East vs. West perspectiveJ Gastrointest Oncol201561798825642341
   PubMed Web of Science ®Google Scholar
• MarkarSRKarthikesalingamAJacksonDHannaGBLong-term survival after gastrectomy for cancer in randomized, controlled oncological trials: comparison between West and EastAnn Surg Oncol20132072328233823340695
   PubMed Web of Science ®Google Scholar